ZLAB Key Statistics, Chart & Performance
The current stock price of ZLAB is 17.64 USD. In the past month the price decreased by -9.63%. In the past year, price decreased by -30.28%.
ZLAB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.18 | 403.83B | ||
| AMGN | AMGEN INC | 14.97 | 176.25B | ||
| GILD | GILEAD SCIENCES INC | 14.99 | 152.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.12 | 115.03B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.15 | 81.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.71 | 52.53B | ||
| INSM | INSMED INC | N/A | 37.12B | ||
| NTRA | NATERA INC | N/A | 31.62B | ||
| BIIB | BIOGEN INC | 10.51 | 25.82B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.46 | 20.98B | ||
| INCY | INCYTE CORP | 15.38 | 19.39B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About ZLAB
Company Profile
Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-09-28. The firm is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The firm has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The firm conducts its businesses within domestic and overseas markets.
Company Info
ZAI LAB LTD-ADR
Building B, 899 Halei Road, Pudong
Shanghai SHANGHAI 201210 CN
CEO: Samantha (Ying) Du
Employees: 1194
Phone: 862161632588
ZAI LAB LTD-ADR / ZLAB FAQ
Can you describe the business of ZAI LAB LTD-ADR?
Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-09-28. The firm is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The firm has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The firm conducts its businesses within domestic and overseas markets.
What is the current price of ZLAB stock?
The current stock price of ZLAB is 17.64 USD. The price increased by 0.06% in the last trading session.
Does ZLAB stock pay dividends?
ZLAB does not pay a dividend.
What is the ChartMill rating of ZAI LAB LTD-ADR stock?
ZLAB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is ZAI LAB LTD-ADR (ZLAB) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ZLAB.
Is ZAI LAB LTD-ADR (ZLAB) expected to grow?
The Revenue of ZAI LAB LTD-ADR (ZLAB) is expected to grow by 27.23% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is ZAI LAB LTD-ADR worth?
ZAI LAB LTD-ADR (ZLAB) has a market capitalization of 1.95B USD. This makes ZLAB a Small Cap stock.
ZLAB Technical Analysis
ZLAB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ZLAB. Both the profitability and financial health of ZLAB have multiple concerns.
ZLAB Financial Highlights
Over the last trailing twelve months ZLAB reported a non-GAAP Earnings per Share(EPS) of -1.88. The EPS increased by 29.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.26% | ||
| ROE | -26.84% | ||
| Debt/Equity | 0.22 |
ZLAB Forecast & Estimates
14 analysts have analysed ZLAB and the average price target is 20.82 USD. This implies a price increase of 18.02% is expected in the next year compared to the current price of 17.64.
For the next year, analysts expect an EPS growth of 31.63% and a revenue growth 27.23% for ZLAB